Literature DB >> 12535574

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

Jiunn H Lin1.   

Abstract

P-glycoprotein (P-gp), the most extensively studied ATP-binding cassette transporter, functions as a biological barrier by extruding toxic substances and xenobiotics out of cells. In vitro and in vivo studies have demonstrated that P-gp plays a significant role in drug absorption and disposition. Like cytochrome P450 enzymes, inhibition and induction of P-gp have been reported as the causes of drug-drug interactions. Because many prototypic inhibitors and inducers affect both CYP3A4 and P-gp, many drug interactions caused by these inhibitors and inducers involve these two systems. Clinically, it is very difficult to quantitatively differentiate P-gp-mediated drug interactions versus CYP3A4-mediated drug interactions, unless their relative contributions can be accurately estimated. Therefore, care should be exercised when interpreting drug interaction data and exploring the underlying mechanisms of drug interactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12535574     DOI: 10.1016/s0169-409x(02)00171-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  51 in total

Review 1.  [Drug interactions. Mechanisms and clinical relevance].

Authors:  U Klotz; W Beil; C Gleiter; B Drewelow; E Garbe; A Gillessen; E Mutschler
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 2.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

4.  Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition.

Authors:  J Cory Kalvass; Gary M Pollack
Journal:  Pharm Res       Date:  2006-12-27       Impact factor: 4.200

Review 5.  Current industrial practices of assessing permeability and P-glycoprotein interaction.

Authors:  Praveen V Balimane; Yong-Hae Han; Saeho Chong
Journal:  AAPS J       Date:  2006-01-13       Impact factor: 4.009

6.  P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?

Authors:  Praveen V Balimane; Anthony Marino; Saeho Chong
Journal:  AAPS J       Date:  2008-12-11       Impact factor: 4.009

7.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

8.  Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Hegang Chen; Andrew Coop; Natalie D Eddington
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

9.  Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

Authors:  Alaa H Abuznait; Shawn G Patrick; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

10.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.